Psoriasis is one of the most common chronic, genetically determined autoimmune, polyetiological inflammatory diseases, in which the skin, joints, internal organs and systems of the body are involved in the pathological process. Despite the significant prevalence of psoriasis and a large number of studies on this problem, there is still no single view on the pathogenesis of this dermatosis. To objectively understand the pathogenesis of psoriasis, it is necessary to take into account the insufficiently studied comorbidity of this pathology. Recently, an indisputable link between psoriasis and obesity has been proven. The scientific literature widely covers the issue of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity. Given the current data on the role of systemic inflammation, it was determined that long-term use of pioglitazone, even in small doses, led to a decrease in systemic inflammation and contributed to a milder course of psoriasis in recurrence of the disease.

Key words: psoriasis, alimentary obesity, pathogenesis, clinical presentation, systemic inflammation, treatment.

Introduction

Psoriasis is the most common chronic, genetically determined autoimmune, polyetiological inflammatory disease with impaired epidermal proliferation, provoked by exogenous and endogenous factors, manifested on the skin by erythematous and scaly papules and plaques with the involvement of the internal organs in the pathogene

*To cite this English version: Yemchenko Ya.O., Ishcheikin K.Ye., Kaidashev I.P. Application of pioglitazone in the comprehensive treatment of psoriatic patients with concomitant alimentary obesity. // The Medical and ecological problems. – 2020. - Vol 24, № 5-6. - P. 7-10.
logical process. According to the results of clinical and epidemiological studies, psoriasis affects about 3–4% of the population of our planet, regardless of sex, age and ethnic group. The causes of psoriasis are immunological disorders and genetic defects. However, despite the significant prevalence of psoriasis and a large number of studies on this problem, there is still no single view on the pathogenesis of this dermatosis, which is associated with insufficiently studied comorbidity of the disease [1].

Recently, there has been a steady trend of increased comorbidity of psoriasis and obesity. Obesity develops due to disorders of metabolism and eating behavior. It is characterized by the accumulation of adipose tissue in the body. Obesity can be both an independent multifactorial disease – primary obesity (alimentary and constitutional), and a syndrome that accompanies the course of other diseases – secondary obesity (symptomatic). In the structure of morbidity, primary obesity occurs in 95% of patients, secondary – only in 5% [2]. A person is considered obese if his/her body mass index (BMI) exceeds 30 kg/m². According to the results of the study, alimentary obesity in patients with psoriasis leads to metabolic disorders complicating the course of dermatosis, leading to worsening of patients’ DLQI, ineffectiveness of standard therapies and frequent exacerbations of psoriasis [3, 4].

Given the current role of systemic inflammation underlying the development of both psoriasis and obesity, the study of the molecular mechanisms of its development and taking into account the role of proinflammatory nuclear transcription factors (NTF), especially NFKB, activator protein-1, and the anti-inflammatory activity of other NTF receptors that are activated by PPAR-γ [5, 6]. Thiazolidinediones (pioglitazone) are the pathogenetically justified drug of choice for the treatment of these diseases. A large number of prospective observations have been accumulated in the scientific literature, indicating a positive effect of pioglitazone in the presence of signs of systemic inflammation. The mechanism of action of this drug is the effect on the suppression of chronic systemic delayed inflammation with low activity. The anti-inflammatory effect of PG is associated with its activating effect on PPARγ receptors, especially PPARγ2 and PPARδ (double agonist PPAR).

The study was approved by the decision of the Committee on Bioethics and Ethical Issues of Ukrainian Medical Stomatological Academy. All patients signed informed consent to participate in the study.

Psoriatic lesions were of extensive nature in all patients. When determining the number of recurrences of psoriasis per year, it was found that recurrence of the disease was observed once in a year in 1 (5%) patient, 2 times a year in 3 (15%) patients, 3 times a year in 11 (55%) patients and 4 times a year in 5 (25%) patients. The PASI (Psoriatic Area and Severity Index) was used to assess the severity of psoriasis [8].

To assess the severity of alimentary obesity in the examined patients, we determined body mass index (BMI) [9]. Subjects with a BMI of 30–40 kg/m² were included in the study.

Determination of systemic inflammation was carried out at the Research Institute for Genetic and Immunological Foundations of Pathology and Pharmagenetics of Ukrainian Medical Stomatological Academy. To assess the severity of systemic inflammation (SI) in the serum of patients, we determined the concentration of interleukin-33 (IL-33), interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP) by enzyme-linked immunosorbent assay on a multichannel photometer “STAT-FAX-303” (USA). For quantification of indicators, we used commercial test systems “interleukin-6-ELISA-BEST” (Russia), “CRP-ELISA-BEST” (Russia), “Human IL-33 ELISA Kit” “eBioscience™ / Affymetrix” (USA) according to the recommended methods. The obtained indicators were compared with those of the reference values recommended by the manufacturers of diagnostic test systems.

Patients received standardized conventional therapy: sedatives, detoxifiers, antihistamines, hepatoprotectors, vitamins and 1-2% salicylic ointment 2 times a day topically for 4 weeks. In order to evaluate the effectiveness of pioglitazone at a dose of 15 mg per day for 6 months in the comprehensive treatment of patients with extensive psoriasis vulgaris of moderate severity, progressive stage, and concomitant alimentary obesity, we evaluated the clinical, laboratory and anthropometric parameters before and after the treatment. Statistical processing of the obtained results was performed using the Statistics 7.0 software. The difference was considered reliable with an error probability P<0.05.

**Results and discussion**

Alimentary obesity was observed in all patients of the study group. When calculating BMI and analyzing indicators in accordance with the classification of obesity by BMI, it was found that 8 (40%) patients had grade I obesity, whereas 12 (60%) patients had grade II obesity. The average group BMI was 37.2 ± 1.7 kg/m².

Based on an objective examination of the clinical presentation, the average PASI index was calculated. It was (21.6 ± 1.5 points), which corresponds to the average severity of psoriasis.

In the study of systemic inflammation, the mean group values of hs-CRP, IL-33 and IL-6 were calculated. In the analysis of the obtained results, it was found that all patients presented with an increased hs-CRP (13.26 ± 1.5 IU/l). 19 patients presented with an increased IL-33 (73.98 ± 7.0 pg/ml), and IL-6 (12.97 ± 1.8 pg/ml), which indicates the presence of a systemic inflammatory process in all examined subjects (Table 1).
Adipocytes and macrophages secrete IL-6 in adipose tissue. Determination of arteriovenous cytokine difference showed an increase in its serum concentration, indicating the secretion of IL-6 by adipose tissue, which produces approximately 30% of circulating IL-6 in the human body. Both leptin and IL-6 production by adipose tissue increase with weight gain [11, 12]. Circulating IL-6 is one of the most important factors determining the production of acute-phase proteins by the liver. It provides a rapid coordinated physiological response to tissue damage or infection, aimed at activating the body's defense mechanisms: the destruction of pathogenic microorganisms, removal of damaged cells and repair of damaged tissues [13]. It should be noted that hs-CRP is one of the most important proteins of the acute phase. It attaches to the membranes of damaged cells and causes their death by activating the reactions of the complement cascade. It is known that hs-CRP is a marker of the IL-6 action [14].

To determine the effectiveness of the obtained treatment for patients with extensive psoriasis vulgaris, moderate severity, progressive stage, and concomitant grade I-II obesity, we studied the clinical, laboratory and anthropometric parameters before and after treatment (Tables 2, 3).

### Table 1

| Indicator       | Value          | Reference value |
|-----------------|----------------|-----------------|
| IL-33, pg/ml    | 73.98±7.0      | 0-54.8          |
| IL-6, pg/ml     | 12.97±1.8      | 0-10            |
| hs-CRP, IU/l    | 13.26±1.5      | 0.068-8.2       |

### Table 2

| Indicator / Value | Before treatment | 14 days after the conducted treatment | 1 month after the conducted treatment | 6 months after the conducted treatment |
|-------------------|------------------|--------------------------------------|---------------------------------------|----------------------------------------|
| PASI, points      | 21.6±1.5         | 10.37±1.2 *                          | 5.9±0.8 *                             | 18.6±1.3                               |
| BMI, kg / m²      | 37.2±1.7         | 37.3±1.6 *                           | 37.3±1.4 *                            | 37.2±1.5 *                             |

Note: statistical processing was performed by the Wilcoxon-Mann-Whitney method Hereinafter: * - p <0.001 as compared to pre-treatment

### Table 3

| Indicator / Value | Before treatment | 6 months after the conducted treatment |
|-------------------|------------------|----------------------------------------|
| IL-33, pg/ml      | 73.98±7.0        | 47.53±6.4 *                            |
| IL-6, pg/ml       | 12.97±1.8        | 8.36±0.9 *                             |
| hs-CRP, IU/l      | 13.26±1.5        | 8.06±0.8 *                             |

When studying the dynamics of the PASI index in patients with extensive psoriasis vulgaris of moderate severity and concomitant grade I-II alimentary obesity, it was found that for 14 days of hospital treatment the rate decreased by 52% from (21.6 ± 1.5 points) to (10.37 ± 1.2), after 1 month – by 73% from (21.6 ± 1.5 points) to (5.9 ± 0.8 points). At the same time, the reduction of the PASI 75 index was observed in 65% of patients, i.e., the obtained results indicate the effectiveness of this therapy. When the corresponding indicator was studied in 6 months, during the next recurrence of psoriasis, there was a decrease in the mean group PASI index by 3.6 points, which is 16.5% as compared to the corresponding indicator before treatment.

No statistically significant changes were observed in the BMI study throughout treatment.

After 6 months of treatment with pioglitazone 15 mg once a day, there was a statistically significant decrease in SI. The mean group value of IL-33 decreased by 26.45 pg / ml, which is 35.8%, IL-6 decreased by 4.6 pg / ml,
which is 35.5%, and hs-CRP decreased by 5.2 IU / l, which is 39.2% as compared to the corresponding indicators before treatment. Our findings are consistent with many other studies showing that thiazolidinediones reduce CRP concentration in obese patients, suppressing the production of proinflammatory cytokines in macrophages by inhibiting nuclear transcription factor NFκB and significantly reducing CRP after 6-26 weeks of treatment as compared to the initial level [16, 17]. Thus, the use of 15 mg of pioglitazone once a day for 6 months in the comprehensive treatment of patients with extensive psoriasis vulgaris of moderate severity and concomitant grade I-II alimentary obesity was effective in terms of the parameters of SI and PASI index. Further, it made it possible to achieve a more favorable course of psoriasis by reducing the PASI index during the next recurrence of the disease.

Conclusions

1. The use of 15 mg of pioglitazone once a day for 6 months in the comprehensive treatment of patients with extensive psoriasis vulgaris of moderate severity and concomitant grade I-II alimentary obesity was effective and led to a decrease in SI and PASI index in recurrence of the disease.

2. Treatment of patients with extensive psoriasis vulgaris of moderate severity and concomitant grade I-II alimentary obesity requires a personalized and comprehensive approach, taking into account the identified comorbidities.

References

1. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. Psoriasis - as an autoimmune disease caused by molecular mimicry. Trends Immunol 2015; 30 (10): 494-501.
2. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity Int J Pediat Obes. 2018; 3: Suppl 1: 37-43.
3. Kaydashev IP. Izmenenie obrazu zhizni, narushenie energeticheskogo metabolizma i sistemnoe vosplalenie kak faktory razvitiya bolezni civilizatsii. Ukrains’kyi medichniy chasopis. 2013; 5: 103-108. [in Ukrainian]
4. Yemchenko Ya. Ri ven pokazyvnyk systemnoho zapalenia u khvorykh na psoriaz oblihazhnyi metabolichnym syndromom. Zhurnal dermatovenereologii ta kosmetologii imeni M.O.Torsueva. 2018; Nr 1 (38):31-35.
5. Kaydashev IP. NF-κB-signalizaciyakak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2-go tipa i ateroskleroza. Mezhdunarodnyy endokrinologicheskiy zhurnal 2013; 3(35): 35-40.
6. Zhao W, Wu C, Li S, Chen X. Adiponectin protects palmitic acid induced endothelial inflammation and insulin resistance via regulating ROS/IKKβ pathways. Cytokine. 2016; 88:167-176.
7. Scherrnhaner G, Craig Currie J, Scherrnhaner G. Do we still need pioglitazone for the treatment of type 2 diabetes. A risk-benefit critique in 2013. Diabetes Care. 2013; 36: 2013-2031.
8. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 00-4084.
9. Fredriksson, T., U. Pettersson. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978, 157(4):238-44.
10. Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M. Serum IL-33 levels are increased in patients with psoriasis. Experimental dermatology. 2015; 3(2):234-239.
11. Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dualfunction alarmins. Cell Mol Immunol. 2017; 14(1):43-64. 12. Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Tolllike receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2017; 27: 84-91.
13. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015; 7 (269):269-274.
14. Bikos C, O’Neill LA. Signaling of toll-like receptors. Handb Exp Pharmacol. 2018; 183: 21-50.
15. Cosmi L, Liotta F, Maggi E. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol. 2014; 164 (3): 171-177.
16. Rasin MS, Rasin SM. Faktory transkripcii v centre sovremennoi biologii i mediciny. Receptory, aktiviruemye prolif- eratorami peroksidom. Likarska sprava. 2013; 3:280-285.
17. Vinnik NI, Kucenko LA. Effektivnost primeneniya pioglitaza- zona v kompleksnoy terapii bolnykh ishemicheskoy boleznyu serdca na fone metabolicheskogo sindroma. Likarska sprava. 2015; 3(4): 67–73 (Ukrainian).

Материал надійшов до редакції 22.10.2020